Trials / Unknown
UnknownNCT05247931
Why Does Aspirin Fail in Secondary Cerebrovascular Prevention? A Multicenter Prospective Case - Control Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Fadoi Foundation, Italy · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter prospective observational case-control study aimed at characterizing the possible determinants of treatment failure in patients with cerebrovascular disease on secondary prevention with ASA, who are hospitalized in Internal Medicine departments for a recurrent atherothrombotic stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine | Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2 |
Timeline
- Start date
- 2019-11-07
- Primary completion
- 2022-04-30
- Completion
- 2022-04-30
- First posted
- 2022-02-21
- Last updated
- 2022-02-21
Locations
16 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT05247931. Inclusion in this directory is not an endorsement.